Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

WHO issues warning about fake weight loss and diabetes drugs

Three fake batches under the brand name Ozempic were detected in the UK, Brazil and the United States last year

Alexander Butler
Thursday 20 June 2024 12:35 EDT
Comments
The WHO issued a warning about fake weight loss and diabetes drugs in the UK. File photo.
The WHO issued a warning about fake weight loss and diabetes drugs in the UK. File photo.

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

Fake weight loss and diabetes drugs have been detected in the UK and around the globe, the World Health Organisation (WHO) warned.

The WHO issued an alert on false semaglutides, the type of medicines that are used for treatment of type two diabetes and obesity in some countries.

Three fake batches branded under Ozempic were detected in the UK in October 2023, Brazil in October 2023 and the United States in December 2023.

The drugs, including the specific brand product that has been falsified, are prescribed to people with type two diabetes in order to lower their blood sugar levels.

The counterfeit drugs could have harmful effects to people’s health and if the products don’t have the necessary raw components, falsified medicines can lead to health complications, the agency warned.

Three fake batches branded under Ozempic were detected in the UK in October 2023, Brazil in October 2023 and the United States in December 2023
Three fake batches branded under Ozempic were detected in the UK in October 2023, Brazil in October 2023 and the United States in December 2023 (PA Wire)

The WHO urged patients using the counterfeit products to buy prescriptions from licenced pharmacies and to avoid purchasing similar products from unverified sources and online.

Dr Yukiko Nakatani, WHO Assistant Director-General for Essential Medicines and Health Products, said: “WHO advises healthcare professionals, regulatory authorities and the public be aware of these falsified batches of medicines.

“We call on stakeholders to stop any usage of suspicious medicines and report to relevant authorities”.

Ozempic can only be prescribed for patients with type two diabetes, and isn’t licensed as a weight loss drug in the UK or the US.

However, the British government acknowledges: “It is not authorised for weight-loss, but it is used off-label for that purpose.”

Dr Alexis Missick from the online pharmacy UK Meds says there are ongoing discussions about the appropriateness and safety of using a drug intended for type 2 diabetes for an off-label purpose, and warned: “Medical experts caution against the casual use of such medications without a proper understanding of their effects and potential risks.

“While Ozempic has shown effectiveness in weight loss, primarily due to its appetite-suppressing properties, it also carries risks including, but not limited to, potential gastrointestinal side-effects.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in